Capricor Therapeutics, Inc. (CAPR, Financial) experienced a significant stock drop of 5.15%, trading at $12.52 per share with a volume of 555,877 shares and a turnover rate of 1.22%. The stock's amplitude reached 8.10%. Recent financial reports indicate revenues of $2.26 million, a net loss of $12.56 million, and earnings per share of -$0.38. The gross profit stood at $1.90 million, with a price-to-earnings ratio of -12.32.
All seven institutions covering the stock recommend buying, with no holds or sells. The biotechnology industry, where Capricor operates, saw an overall decline of 1.80%. Notably, Polyrizon Ltd., Tc Biopharm (Holdings) Plc, and Cardio Diagnostics Holdings Inc. recorded significant gains. Active stocks included Polyrizon Ltd., Cognition Therapeutics, Inc., and Tc Biopharm (Holdings) Plc, with high turnover rates.
Capricor focuses on developing transformative cell and exosome therapies for rare diseases, with products like CAP-1002 and deramiocel, which is in Phase 3 for Duchenne muscular dystrophy.
